Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage small molecule precision medicine company, said management will participate in two fireside chats in September 2026. The company is scheduled for the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, at 1:30 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, at 9:15 a.m. ET. Both sessions will be webcast live through the Events section of Relay Therapeutics’ investor relations website, with archived replays available for up to 30 days. Relay develops therapies for cancer and genetic disease via its Dynamo platform; its lead asset, zovegalisib, is a pan-mutant selective PI3Kα inhibitor in Phase 3 testing for HR+/HER2- metastatic breast cancer and is also being studied in PI3Kα-driven vascular anomalies, alongside pipeline work in NRAS-driven solid tumors and Fabry disease.